Kim Jong Joseph, Chief Executive Officer, added 22,500 shares of Inovio Pharmaceuticals, Inc. (INO) to its portfolio at the rate of $3.11 per share valuing $69,975 on Jan 13. The insider has now 1,100,707 shares of the company to its portfolio. Currently, the 1st Resistance Point for this stock is $3.48, with a 2nd Resistance Point sitting at $3.66. Meanwhile, this company’s stock has a 1st Support Level at $3.10 and a 2nd Support Level at $2.90. Before making a move on any particular stock, readers often pay close attention to support and resistance markers. The last reported price for shares of Inovio Pharmaceuticals, Inc. (INO) was $3.31. Inovio Pharmaceuticals, Inc. (INO) stock has gained $0.17, or 5.41%, in the past five days. In the last full month, these shares have gained $0.59, or 21.69%. In the past three months, this stock’s price has risen by $1.13, or 51.83%. This year-to-date, Inovio Pharmaceuticals, Inc. (INO) shares have gained $0.01, or 0.30%.
Analyzing price projection indicators is a helpful way to determine whether a potential stock buy is a wise choice for profits in the short term, medium term, and long term. For Inovio Pharmaceuticals, Inc. (INO) stock, 100% of short-term indicators suggest that these shares are a “ Buy .” Meanwhile, 50% of medium-term indicators point to this stock being a “ Buy .” Looking further ahead, 50% of long-term indicators suggest that this stock is a “ Buy .”
With 100,010 K shares outstanding, this company currently has a market capitalization of $311,031K. Inovio Pharmaceuticals, Inc. (INO) generates $30,480 K in annual sales, amounting to annual net income of -$96,970 K. This stock has generated a 1-Year Total Return of -31.61%, a 3-Year Total Return of -55.44%, and a 5-year Total Return of -64.54%. This stock’s 5-Year Dividend Growth is 0.00%. Its Annual Dividend Yield is 0.00%, and its Annual Dividend Rate is 0.00.
In the most recently-reported fiscal quarter, which ended in 09/19, Inovio Pharmaceuticals, Inc. (INO) reported earnings of -$0.27 per share. Wall Street analysts, on average, were expecting the company to report earnings of -$0.27 per share, representing equal. In the previous quarter ending in 06/19, the reported earnings of -$0.30 represented a -0.02 difference from the consensus estimate calling for -$0.28 per share, which was a -7.14% surprise.
For the current fiscal quarter, which is set to end in 12/2019, the average earnings estimate is -$0.23 per share. This estimate came from a total of 4 Wall Street Analysts. Of those market experts, the high estimate was -$0.23 and the low estimate was -$0.24. In the year-ago quarter, Inovio Pharmaceuticals, Inc. (INO) generated per-share earnings of -$0.34. If the analysts are correct about the current quarter’s earnings, the growth will be +32.35%.
Turning our focus now to insider trading activity, there have been 2 purchases (8,180 shares in total) and 0 sale (0 shares in total) in the last 3 months. In the last 6 months, there have been 3 insider buys amounting to 12,680 shares and 1 insider sales amounting to 16,352 shares. In the past full year, 22 insider purchases were made (involving 501,375 shares) and 17 insider sell-offs equivalent to 2,499,457 shares.
Moving onto liquidity, Inovio Pharmaceuticals, Inc. (INO) has a Current Ratio of 2.49, a Quick Ratio of 2.49 and a Cash Ratio of 2.30.